A Study of SHR6508 in Secondary Hyperparathyroidism
Status:
Not yet recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the efficacy and safety of SHR6508 for Chinese
patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance
hemodialysis.